Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Long-Term Deferred Tax (2016 - 2025)

Iradimed (IRMD) has disclosed Long-Term Deferred Tax for 12 consecutive years, with $2.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Long-Term Deferred Tax fell 1.71% to $2.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.4 million, a 1.71% decrease, with the full-year FY2024 number at $2.8 million, up 32.86% from a year prior.
  • Long-Term Deferred Tax was $2.4 million for Q3 2025 at Iradimed, down from $2.6 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $2.8 million in Q4 2024 to a low of $622206.0 in Q1 2023.
  • A 5-year average of $1.6 million and a median of $1.8 million in 2023 define the central range for Long-Term Deferred Tax.
  • Peak YoY movement for Long-Term Deferred Tax: tumbled 60.15% in 2021, then surged 202.88% in 2023.
  • Iradimed's Long-Term Deferred Tax stood at $765096.0 in 2021, then dropped by 8.39% to $700867.0 in 2022, then soared by 202.88% to $2.1 million in 2023, then surged by 32.86% to $2.8 million in 2024, then decreased by 14.11% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Long-Term Deferred Tax are $2.4 million (Q3 2025), $2.6 million (Q2 2025), and $2.7 million (Q1 2025).